Nature Medicine, Published online: 30 May 2025; doi:10.1038/s41591-025-03744-1
As presented at the 2025 ASCO Annual Meeting: in cohort 3 of the phase 2 TUXEDO-3 trial, patients with leptomeningeal metastatic disease from any solid tumor were treated with the HER3-targeting antibody–drug conjugate patritumab deruxtecan and showed encouraging 3-month overall survival rates.- May 30, 2025
- 0 Comment
Nature Medicine, Published online: 29 May 2025; doi:10.1038/s41591-025-03720-9
African countries have made progress in expanding their genomics and bioinformatics workforces for public health, yet several barriers pose risks to workforce retention and long-term sustainability.- May 29, 2025
- 0 Comment
Nature Medicine, Published online: 29 May 2025; doi:10.1038/d41591-025-00035-7
Researchers studied the antibody library of a venom-immune person with extensive snakebite exposure — and generated a three-agent, broadly neutralizing cocktail that protected mice against venoms from high-priority species.- May 29, 2025
- 0 Comment
Nature Medicine, Published online: 29 May 2025; doi:10.1038/d41591-025-00034-8
GLP-1 receptor agonist semaglutide significantly outperformed placebo in an ongoing phase 3 trial, showing reductions in steatohepatitis and liver fibrosis, in addition to cardiometabolic benefits.- May 29, 2025
- 0 Comment
Nature Medicine, Published online: 29 May 2025; doi:10.1038/s41591-025-03766-9
Rebuilding global health after the demise of USAID- May 29, 2025
- 0 Comment
Since 2009, Nexira has been working in partnership with the NGO SOS SAHEL, finished product brands, and local organizations supporting sustainable acacia forest development in Chad.
- May 28, 2025
- 0 Comment
Nature Medicine, Published online: 28 May 2025; doi:10.1038/s41591-025-03732-5
This large integrated analysis of the KRASG12C inhibitor sotorasib clinical efficacy biomarkers from the phase 2 CodeBreaK 100 and phase 3 CodeBreaK 200 trials shows that low expression of TTF-1 and high expression of NRF2 determine anti-tumor efficacy of sotorasib in non–small-cell lung cancer.- May 28, 2025
- 0 Comment
Nature Medicine, Published online: 28 May 2025; doi:10.1038/s41591-025-03736-1
Lifeline: a musical about antimicrobial resistance that raises awareness and inspires action- May 28, 2025
- 0 Comment
Nature Medicine, Published online: 28 May 2025; doi:10.1038/s41591-025-03729-0
Here we propose six recommendations for researchers to consider for the successful implementation of evidence-based digital health interventions into routine clinical practice.- May 28, 2025
- 0 Comment
Nature Medicine, Published online: 27 May 2025; doi:10.1038/s41591-025-03704-9
In a post-hoc analysis of circulating tumor DNA (ctDNA) features from patients with metastatic prostate cancer treated with [177Lu]Lu–PSMA-617 or cabazitaxel in the randomized phase 2 TheraP trial, low ctDNA levels at baseline were predictive of clinical benefit from [177Lu]Lu–PSMA-617, and PTEN or ATM alterations were identified as potential biomarkers of response.- May 27, 2025
- 0 Comment
